ClinicalTrials.gg
CompletedNCT00215436Updated Nov 10, 2010

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

A Phase 3 interventional study of Formoterol Fumarate in COPD, sponsored by Dey. Completed at 44 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-11-10.

Sponsored by Dey (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
33rd of 89
345 · median 120
Started
2005
with 5 others
Phase 3
40 of 89
1 open now
Registered
4th of 89
by date
Lead sponsor
11 of 89
Dey

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 33rd largest by enrollment, is one of 6 that started in 2005, is one of 40 in phase 3, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.

03

Conditions studied

  • COPD

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • formoterol
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical diagnosis of
  • Current or prior history of cigarette smoking

Exclusion criteria

Exclusion Criteria:

  • Medical diagnosis of asthma
  • Chest X-ray diagnostic of significant disease other than
  • Significant condition or disease other than COPD
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
345 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Measure of lung function

Secondary outcomes

  1. Change in lung function, as well as vital signs

  2. Physical Exam results, Adverse event reporting, etc

07

Study locations

44 sites
  • Research Site
    Jasper, Alabama 35501, United States
  • Research Site
    Phoenix, Arizona 85006-2666, United States
  • Research Site
    Tuscon, Arizona 85715, United States
  • Research Site
    Buena Park, California 90620, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    Stockton, California 95207, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Hartford, Connecticut 06105, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Woodstock, Georgia 30189, United States
  • Research Site
    Hines, Illinois 60141, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Florence, Kentucky 41042, United States
  • Research Site
    New Orleans, Louisiana 70115, United States
  • Research Site
    Ann Arbor, Michigan 48106, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    St Charles, Missouri 63301, United States
  • Research Site
    St. Louis, Missouri 63122, United States
  • Research Site
    Butte, Montana 59701, United States
  • Research Site
    Henderson, Nevada 89014, United States
  • Research Site
    Cherry Hill, New Jersey 08003, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    Albuquerque, New Mexico 87108, United States
  • Research Site
    Camillus, New York 13031, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Cincinnati, Ohio 45241, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Cranston, Rhode Island 02920, United States
  • Research Site
    Spartanburg, South Carolina 29307, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Richmond, Virginia 23225, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Milwaukee, Wisconsin 53209, United States
08

References and documents

Publications

  • Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Oct;29(10):2167-78. doi: 10.1016/j.clinthera.2007.10.007. Erratum In: Clin Ther. 2009 Apr;31(4):920. PubMed 18042473 ↗
  • Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008 Feb;102(2):189-97. doi: 10.1016/j.rmed.2007.10.007. PubMed 18363201 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Sep 2005 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Mar 2005
Primary completionActual
Sep 2005
CompletionActual
Sep 2006
Last update
Nov 10, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00215436
Lead sponsor
Dey
First posted
Sep 22, 2005
Start date
Mar 2005
Primary completion
Sep 2005
Completion
Sep 2006
Last update
Nov 10, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion